Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 15/20 | 0.43 |
| ▸ | LIPC | P11150 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.34 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL754205 | 0.84 | LIPG (0.47) | LIPGLIPCCNR2GPR55PDE3B | |
| SCHEMBL752850 | 0.84 | LIPG (0.47) | LIPGLIPCCNR2GPR55HSP90AA1 | |
| SCHEMBL754111 | 0.81 | LIPG (0.45) | LIPGLIPCCNR2GPR55HSP90AA1 | |
| SCHEMBL754228 | 0.81 | LIPG (0.42) | LIPGLIPCHSP90AA1 | |
| SCHEMBL753861 | 0.81 | LIPG (0.43) | LIPGLIPCCNR2GPR55HSP90AA1 | |
| SCHEMBL754083 | 0.78 | LIPG (0.45) | LIPGLIPCCNR2GPR55HSP90AA1 | |
| SCHEMBL753687 | 0.78 | LIPG (0.43) | LIPGLIPCCNR2GPR55PDE3B | |
| SCHEMBL755038 | 0.78 | POLB (0.40) | OPRM1OPRD1CNR2GPR55PDE3B | |
| SCHEMBL2489939 | 0.77 | LIPG (0.49) | LIPGLIPCHSP90AA1 | |
| SCHEMBL2777643 | 0.77 | LIPG (0.41) | LIPGLIPCCNR2GPR55HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170066754-A1 | ANTIVIRAL AGENT | SHIONOGI & CO., LTD. (JP) | 2017-03-09 | — | — | US | disclosed |
| US-9572813-B2 | Antiviral agent | SHIONOGI & CO., LTD. (JP) | 2017-02-21 | — | — | US | disclosed |
| US-20150202208-A1 | ANTIVIRAL AGENT | SHIONOGI & CO., LTD. (JP) | 2015-07-23 | — | — | US | disclosed |
| EP-1422218-B1 | ANTIVIRAL AGENT | SHIONOGI & CO (JP) | 2012-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150202208-A1 | ANTIVIRAL AGENT | ZC3HAV1, ZC3HAV1L, CCNI | LIPG 4229/4885LIPC 3817/4885OPRM1 867/4885 |
| US-20170066754-A1 | ANTIVIRAL AGENT | ZC3HAV1, ZC3HAV1L, CCNI | LIPG 4229/4885LIPC 3817/4885OPRM1 867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.